PDCD1 and malignant pleural mesothelioma: Combination immune checkpoint inhibitor (ICI) therapy with nivolumab, targeting programmed cell death protein 1 (PD‐1), and ipilimumab, targeting cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4), improves survival in malignant pleural mesothelioma (MPM).